White House Nominates Domestic Policy Advisor Heidi Overton to Helm Food and Drug Administration

WASHINGTON, DC — President Donald Trump formally announced Wednesday evening the nomination of Dr. Heidi Overton, current deputy director of the White House Domestic Policy Council, to serve as Commissioner of the Food and Drug Administration (FDA).

Professional Background and Policy Focus

Dr. Overton, a preventive medicine specialist and health policy researcher with graduate training from the Johns Hopkins Bloomberg School of Public Health, has served as a senior architect of the administration's chronic disease and regulatory reform initiatives. Her nomination received immediate endorsement from Health and Human Services Secretary Robert F. Kennedy Jr., who praised her focus on addressing metabolic health, pediatric chronic illnesses, and food supply additive standards.

In statements released through the transition office, Dr. Overton outlined priorities to modernize clinical trial approvals, expedite domestic pharmaceutical manufacturing permits, and increase public access to underlying clinical safety data.

Senate Confirmation Outlook

Her confirmation proceedings before the Senate Health, Education, Labor and Pensions (HELP) Committee are anticipated to generate rigorous questioning from both parties regarding drug safety review timelines, vaccine evaluation protocols, and agency staff reorganizations.

Biopharmaceutical industry groups expressed optimism regarding proposed regulatory streamlining while emphasizing the necessity of maintaining gold-standard efficacy benchmarks.

Committee Hearing Schedule

Senate HELP Committee Chairman Bill Cassidy announced that confirmation hearings for the FDA nomination will be scheduled shortly after the Senate reconvenes in early September 2026.